Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Johnson & Johnson gets grant for surgical instrument for harvesting tendon grafts
Johnson & Johnson has been granted a patent for a surgical instrument designed for harvesting tendon grafts. The instrument features...
Erdafitinib by Johnson & Johnson for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Head And Neck Squamous Cell...
Erdafitinib by Johnson & Johnson for Soft Tissue Sarcoma: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Soft Tissue Sarcoma. According to...
Daratumumab by Johnson & Johnson for Antiphospholipid Syndrome: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Antiphospholipid Syndrome. According to GlobalData,...
Daratumumab by Johnson & Johnson for Lupus Nephritis: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lupus Nephritis. According to GlobalData,...
Nipocalimab by Johnson & Johnson for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Nipocalimab is under clinical development by Johnson & Johnson and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)....
Guselkumab by Johnson & Johnson for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Guselkumab is under clinical development by Johnson & Johnson and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According to...
Erdafitinib by Johnson & Johnson for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Squamous Non-Small Cell Lung Cancer....
Daratumumab by Johnson & Johnson for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
Gemcitabine by Johnson & Johnson for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Gemcitabine is under clinical development by Johnson & Johnson and currently in Phase III for Non Muscle Invasive Bladder Cancer...
Daratumumab by Johnson & Johnson for T-Cell Leukemia: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for T-Cell Leukemia. According to GlobalData,...
Daratumumab by Johnson & Johnson for Primary Systemic Amyloidosis: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Primary Systemic Amyloidosis. According to...
Daratumumab by Johnson & Johnson for Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoma. According to GlobalData, Phase...
Daratumumab by Johnson & Johnson for Systemic Lupus Erythematosus: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Systemic Lupus Erythematosus. According to...
Daratumumab by Johnson & Johnson for POEMS Syndrome (Crow-Fukase Syndrome): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for POEMS Syndrome (Crow-Fukase Syndrome). According...
Daratumumab by Johnson & Johnson for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. According...
Daratumumab by Johnson & Johnson for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Daratumumab by Johnson & Johnson for Lymphoblastic Lymphoma: Likelihood of Approval
Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData,...
Johnson & Johnson gets grant for expandable apparatus for electrophysiological sensing with staggered electrodes
Johnson & Johnson has been granted a patent for an apparatus designed for electrophysiological sensing. The apparatus includes a shaft...
Johnson & Johnson files patent for an apparatus for minimizing rotation of a staple driver
Johnson & Johnson has filed a patent for an apparatus that includes a staple, a body, a staple driver, and...